What is BofA Securities's price target for BEAM?

BofA Securities's latest stated price target for Beam Therapeutics Inc. (BEAM) is $42, from its action on Mar 28, 2025.

What is BofA Securities's rating on BEAM?

BofA Securities rates BEAM Buy, a bullish rating, as of Mar 28, 2025.

When did BofA Securities last change its view on BEAM?

On Mar 28, 2025, BofA Securities upgrades to Buy from Neutral, price target $42.

BofA Securities BEAM price target and rating history

Beam Therapeutics Inc. (BEAM) · Health Care

BofA Securities rates Beam Therapeutics Inc. (BEAM) Buy with a $42 price target, as of its latest action on Mar 28, 2025. It has published 3 rating actions on BEAM since September 2021, including 1 upgrade and 1 downgrade.

Current rating: Buy
Price target: $42
Median target, all firms: Too few
Actions on BEAM: 3

BofA Securities price target on BEAM

BofA Securities price target on BEAM, each point a stated target, September 2021 to March 2025.

Every BofA Securities rating on BEAM

Mar 28, 2025
UpgradeBofA Securities upgrades to Buy from Neutral, price target $42
Dec 15, 2023
DowngradeBofA Securities downgrades to Neutral from Buy, price target $35
Sep 10, 2021
InitiateBofA Securities starts coverage at Buy, price target $150

Questions about BofA Securities and BEAM

What is BofA Securities's price target for BEAM?: BofA Securities's latest stated price target for Beam Therapeutics Inc. (BEAM) is $42, from its action on Mar 28, 2025.
What is BofA Securities's rating on BEAM?: BofA Securities rates BEAM Buy, a bullish rating, as of Mar 28, 2025.
When did BofA Securities last change its view on BEAM?: On Mar 28, 2025, BofA Securities upgrades to Buy from Neutral, price target $42.

More BEAM rating histories

All BofA Securities ratings BEAM news and filings Every analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.